Referencia número: HY-N0842

Bevirimat

(Synonyms: PA-457; MPC-4326; YK FH312)

2 Cited Publications

Revisión del cliente

Based on 2 publication(s) in Google Scholar

Bevirimat (PA-457, MPC-4326, YK FH312) is an inhibitor of HIV-1 viral particle maturation.Bevirimat specifically inhibits the final rate-limiting step in Gag processing, preventing the release of the mature capsid protein (CA) from its precursor (CA-SP1), resulting in the production of immature non-infectious viral particles. Bevirimat can be used in HIV-1 infection studies.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.82%
No. CAS: 174022-42-5
Fòrmula: C₃₆H₅₆O₆
Peso molecular:584.83

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Bevirimat Chemical Structure

No. CAS: 174022-42-5

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- Cellular Effect
- In Vitro
- In Vivo
- Ensayo clínico
Chemical Information
Publications (2)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Bioz

Actividad biológica

Descripciòn

Cellular Effect

Cell Line	Type	Value	Description	References
H9	IC₅₀	7 μM Compound: 2	Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days	[PMID: 11141100]
H9	EC₅₀	<0.00035 μM Compound: 2	Cytotoxicity against mock-infected human H9 cells Cytotoxicity against mock-infected human H9 cells	[PMID: 11141100]
H9	EC₅₀	<0.35 nM Compound: 2	Cytotoxicity against mock-infected human H9 cells Cytotoxicity against mock-infected human H9 cells	[PMID: 11141100]
H9	EC₅₀	<0.00035 μM Compound: 2	Evaluated for the anti-HIV activity against HIV-1 replication in H9 lymphocyte cells Evaluated for the anti-HIV activity against HIV-1 replication in H9 lymphocyte cells	[PMID: 11206454]
H9	EC₅₀	<0.35 nM Compound: 2	Evaluated for the anti-HIV activity against HIV-1 replication in H9 lymphocyte cells Evaluated for the anti-HIV activity against HIV-1 replication in H9 lymphocyte cells	[PMID: 11206454]
H9	IC₅₀	7 μM Compound: 2 (PA-457)	Concentration required to produce 50% toxicity against mock-infected H9 cells Concentration required to produce 50% toxicity against mock-infected H9 cells	[PMID: 15501054]
H9	EC₅₀	0.007 μM Compound: 8	Antiviral activity against HIV1 3B in H9 lymphocytes Antiviral activity against HIV1 3B in H9 lymphocytes	[PMID: 16942019]
H9	IC₅₀	>42.8 μM Compound: 8	Cytotoxicity against human H9 lymphocytes Cytotoxicity against human H9 lymphocytes	[PMID: 16942019]
H9	IC₅₀	7 μM Compound: 133, DSB, PA-457, MPC-4326	Antiviral activity against HIV1 infected in human H9 cells after 4 days by p24 antigen ELISA Antiviral activity against HIV1 infected in human H9 cells after 4 days by p24 antigen ELISA	[PMID: 20187635]
H9	EC₅₀	0.00035 μM Compound: 133, DSB, PA-457, MPC-4326	Cytotoxicity against human H9 cells after 4 days by coulter counter Cytotoxicity against human H9 cells after 4 days by coulter counter	[PMID: 20187635]
H9	EC₅₀	0.35 nM Compound: 133, DSB, PA-457, MPC-4326	Cytotoxicity against human H9 cells after 4 days by coulter counter Cytotoxicity against human H9 cells after 4 days by coulter counter	[PMID: 20187635]
H9	EC₅₀	>3.5 x 10^-4 μM Compound: 2, DSB, PA-457	Antiviral activity against HIV infected in H9 cells Antiviral activity against HIV infected in H9 cells	[PMID: 23399723]
H9	EC₅₀	0.35 nM Compound: 1; BVM	Antiviral activity against HIV1 infected in human H9 cells Antiviral activity against HIV1 infected in human H9 cells	[PMID: 26968652]
H9	EC₅₀	<3.5 μM Compound: 3	Toxic concentration on HIV-1 mock infected H9 lymphocyte cells Toxic concentration on HIV-1 mock infected H9 lymphocyte cells	[PMID: 8676334]
H9	IC₅₀	7 μM Compound: 3	Inhibitory activity against HIV-1 replication in mock infected H9 cells Inhibitory activity against HIV-1 replication in mock infected H9 cells	[PMID: 8676334]
H9	IC₅₀	>7 μM Compound: 2	Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound toxic to 50% of mock-infected H9 cells. Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound toxic to 50% of mock-infected H9 cells.	[PMID: 9804704]
H9	EC₅₀	<0.00035 μM Compound: 2	Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%. Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%.	[PMID: 9804704]
H9	EC₅₀	<0.35 nM Compound: 2	Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%. Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%.	[PMID: 9804704]
H9	EC₅₀	0.00035 μM Compound: 3, bevirimat, DSB, PA-457	Antiviral activity against Human immunodeficiency virus 1 infected human H9 cells assessed as inhibition of viral replication Antiviral activity against Human immunodeficiency virus 1 infected human H9 cells assessed as inhibition of viral replication	10.1007/s00044-010-9467-2
H9	EC₅₀	0.35 nM Compound: 3, bevirimat, DSB, PA-457	Antiviral activity against Human immunodeficiency virus 1 infected human H9 cells assessed as inhibition of viral replication Antiviral activity against Human immunodeficiency virus 1 infected human H9 cells assessed as inhibition of viral replication	10.1007/s00044-010-9467-2
HeLa	EC₅₀	>1 μM Compound: DSB	Antiviral activity against HIV1 harboring spacer peptide A1V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay Antiviral activity against HIV1 harboring spacer peptide A1V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 19805571]
HeLa	EC₅₀	0.009 μM Compound: DSB	Antiviral activity against wild type HIV1 infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay Antiviral activity against wild type HIV1 infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 19805571]
HeLa	EC₅₀	0.29 μM Compound: DSB	Antiviral activity against HIV1 harboring capsid I201V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay Antiviral activity against HIV1 harboring capsid I201V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 19805571]
MT2	IC₅₀	>42.78 μM Compound: 2	Cytotoxicity against MT2 cells by XTT assay Cytotoxicity against MT2 cells by XTT assay	[PMID: 17935987]
MT2	CC₅₀	40 μM Compound: 2	Cytotoxicity against human MT2 cells by XTT assay Cytotoxicity against human MT2 cells by XTT assay	[PMID: 19388685]
MT2	EC₅₀	0.011 μM Compound: 2	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as p24 antigen level after 4 days by ELISA Antiviral activity against HIV1 3B infected in human MT2 cells assessed as p24 antigen level after 4 days by ELISA	[PMID: 19388685]
MT2	EC₅₀	34 nM Compound: BVM	Antiviral activity against Human immunodeficiency virus 1 LAI infected in human MT-2 cells by XTT-assay Antiviral activity against Human immunodeficiency virus 1 LAI infected in human MT-2 cells by XTT-assay	[PMID: 20308382]
MT2	EC₅₀	0.0013 μM Compound: 2, Bevirimat	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral replication treated 1 day after infection measured on after 4 days postinfection by p24 antigen ELISA Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral replication treated 1 day after infection measured on after 4 days postinfection by p24 antigen ELISA	[PMID: 20329730]
MT2	IC₅₀	42.78 μM Compound: 2, Bevirimat	Cytotoxicity against human MT2 cells by XTT assay Cytotoxicity against human MT2 cells by XTT assay	[PMID: 20329730]
MT2	EC₅₀	0.005 nM Compound: PA-457	Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.005 multiplicities of infection after 6 days Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.005 multiplicities of infection after 6 days	[PMID: 20660667]
MT2	EC₅₀	0.05 nM Compound: PA-457	Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.05 multiplicities of infection after 6 days Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.05 multiplicities of infection after 6 days	[PMID: 20660667]
MT2	EC₅₀	0.5 nM Compound: PA-457	Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.5 multiplicities of infection after 6 days Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.5 multiplicities of infection after 6 days	[PMID: 20660667]
MT2	CC₅₀	>10 μM Compound: bevirimat	Cytotoxicity against mock-infected human MT2 cells assessed as reduction in cell viability incubated for 48 hrs by cell-titer Glo assay Cytotoxicity against mock-infected human MT2 cells assessed as reduction in cell viability incubated for 48 hrs by cell-titer Glo assay	[PMID: 25927586]
MT2	IC₅₀	0.01 μM Compound: bevirimat	Antiviral activity against HIV1 NL4.3-Ren infected in human MT2 cells assessed as inhibition of viral growth measured 48 hrs post infection by luminometry Antiviral activity against HIV1 NL4.3-Ren infected in human MT2 cells assessed as inhibition of viral growth measured 48 hrs post infection by luminometry	[PMID: 25927586]
MT2	CC₅₀	16.8 μM Compound: 1; BVM	Cytotoxicity against human MT2 cells assessed as cell viability by redox dye assay Cytotoxicity against human MT2 cells assessed as cell viability by redox dye assay	[PMID: 26968652]
MT2	EC₅₀	0.01 μM Compound: 1; BVM	Antiviral activity against wild type HIV1 NLRepRlucP373S infected in human MT2 cells after 4 to 5 days by luciferase report gene based multiple cycle drug susceptibility assay Antiviral activity against wild type HIV1 NLRepRlucP373S infected in human MT2 cells after 4 to 5 days by luciferase report gene based multiple cycle drug susceptibility assay	[PMID: 26968652]
MT2	EC₅₀	0.553 μM Compound: 1; BVM	Antiviral activity against HIV1 containing gag V370A mutant infected in human MT2 cells after 4 to 5 days by luciferase report gene based multiple cycle drug susceptibility assay Antiviral activity against HIV1 containing gag V370A mutant infected in human MT2 cells after 4 to 5 days by luciferase report gene based multiple cycle drug susceptibility assay	[PMID: 26968652]
MT2	EC₅₀	0.974 μM Compound: 1; BVM	Antiviral activity against wild type HIV1 NLRepRlucP373S infected in human MT2 cells after 4 to 5 days in presence of 15 mg/ml HSA by luciferase report gene based multiple cycle drug susceptibility assay Antiviral activity against wild type HIV1 NLRepRlucP373S infected in human MT2 cells after 4 to 5 days in presence of 15 mg/ml HSA by luciferase report gene based multiple cycle drug susceptibility assay	[PMID: 26968652]
MT2	CC₅₀	17 μM Compound: 2; BVM	Cytotoxicity against human MT2 cells Cytotoxicity against human MT2 cells	[PMID: 26988305]
MT2	EC₅₀	10 nM Compound: 2; BVM	Antiviral activity against wild type HIV1 NL4-3 infected in human MT2 cells after 4 to 5 days by dual-luciferase reporter gene assay Antiviral activity against wild type HIV1 NL4-3 infected in human MT2 cells after 4 to 5 days by dual-luciferase reporter gene assay	[PMID: 26988305]
MT2	EC₅₀	1810 nM Compound: 2; BVM	Antiviral activity against wild type BVM-resistant HIV1 NL4-3 habouring Gag protein V370M mutant infected in human MT2 cells after 4 to 5 days by dual-luciferase reporter gene assay Antiviral activity against wild type BVM-resistant HIV1 NL4-3 habouring Gag protein V370M mutant infected in human MT2 cells after 4 to 5 days by dual-luciferase reporter gene assay	[PMID: 26988305]
MT2	EC₅₀	40 nM Compound: 2; BVM	Antiviral activity against wild type BVM-resistant HIV1 NL4-3 habouring Gag protein T371A mutant infected in human MT2 cells after 4 to 5 days by dual-luciferase reporter gene assay Antiviral activity against wild type BVM-resistant HIV1 NL4-3 habouring Gag protein T371A mutant infected in human MT2 cells after 4 to 5 days by dual-luciferase reporter gene assay	[PMID: 26988305]
MT2	EC₅₀	553 nM Compound: 2; BVM	Antiviral activity against wild type HIV1 NL4-3 habouring Gag protein V370A mutant infected in human MT2 cells after 4 to 5 days by dual-luciferase reporter gene assay Antiviral activity against wild type HIV1 NL4-3 habouring Gag protein V370A mutant infected in human MT2 cells after 4 to 5 days by dual-luciferase reporter gene assay	[PMID: 26988305]
MT2	EC₅₀	77 nM Compound: 2; BVM	Antiviral activity against wild type BVM-resistant HIV1 NL4-3 habouring Gag protein delta T371 infected in human MT2 cells after 4 to 5 days by dual-luciferase reporter gene assay Antiviral activity against wild type BVM-resistant HIV1 NL4-3 habouring Gag protein delta T371 infected in human MT2 cells after 4 to 5 days by dual-luciferase reporter gene assay	[PMID: 26988305]
MT2	EC₅₀	974 nM Compound: 2; BVM	Antiviral activity against wild type HIV1 NL4-3 infected in human MT2 cells after 4 to 5 days by dual-luciferase reporter gene assay in presence of human serum albumin Antiviral activity against wild type HIV1 NL4-3 infected in human MT2 cells after 4 to 5 days by dual-luciferase reporter gene assay in presence of human serum albumin	[PMID: 26988305]
MT2	EC₅₀	>10000 nM Compound: 2; BVM	Antiviral activity against wild type HIV1 NL4-3 habouring Gag protein delta V370 infected in human MT2 cells after 4 to 5 days by dual-luciferase reporter gene assay Antiviral activity against wild type HIV1 NL4-3 habouring Gag protein delta V370 infected in human MT2 cells after 4 to 5 days by dual-luciferase reporter gene assay	[PMID: 26988305]
MT2	CC₅₀	16.8 nM Compound: 1	Cytotoxicity against human MT2 cells Cytotoxicity against human MT2 cells	[PMID: 27326328]
MT2	EC₅₀	10 nM Compound: 1	Binding affinity to gag polyprotein in wild type HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay Binding affinity to gag polyprotein in wild type HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay	[PMID: 27326328]
MT2	EC₅₀	1114 nM Compound: 1	Binding affinity to gag polyprotein V370A/T371 deletion mutant in HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay Binding affinity to gag polyprotein V370A/T371 deletion mutant in HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay	[PMID: 27326328]
MT2	EC₅₀	1291 nM Compound: 1	Binding affinity to gag polyprotein in wild type HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum/40% human serum by dual-luciferase reporter assay Binding affinity to gag polyprotein in wild type HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum/40% human serum by dual-luciferase reporter assay	[PMID: 27326328]
MT2	EC₅₀	1810 nM Compound: 1	Binding affinity to gag polyprotein V370M mutant in HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay Binding affinity to gag polyprotein V370M mutant in HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay	[PMID: 27326328]
MT2	EC₅₀	40 nM Compound: 1	Binding affinity to gag polyprotein V371A deletion mutant in HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay Binding affinity to gag polyprotein V371A deletion mutant in HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay	[PMID: 27326328]
MT2	EC₅₀	552 nM Compound: 1	Binding affinity to gag polyprotein V370A mutant in HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay Binding affinity to gag polyprotein V370A mutant in HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay	[PMID: 27326328]
MT2	EC₅₀	7 nM Compound: 1	Binding affinity to gag polyprotein Q369H mutant in HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay Binding affinity to gag polyprotein Q369H mutant in HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay	[PMID: 27326328]
MT2	EC₅₀	74 nM Compound: 1	Binding affinity to gag polyprotein V3621 mutant in HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay Binding affinity to gag polyprotein V3621 mutant in HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay	[PMID: 27326328]
MT2	EC₅₀	77 nM Compound: 1	Binding affinity to gag polyprotein T371 deletion mutant in HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay Binding affinity to gag polyprotein T371 deletion mutant in HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay	[PMID: 27326328]
MT2	EC₅₀	>10000 nM Compound: 1	Binding affinity to gag polyprotein V370A deletion mutant in HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay Binding affinity to gag polyprotein V370A deletion mutant in HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay	[PMID: 27326328]
MT2	CC₅₀	17 μM Compound: 1; BVM	Cytotoxicity against human MT2 cells Cytotoxicity against human MT2 cells	[PMID: 29631960]
MT2	CC₅₀	16.8 μM Compound: 1; BVM	Cytotoxicity against human MT2 cells Cytotoxicity against human MT2 cells	[PMID: 33508465]
MT2	CC₅₀	17 μM Compound: 2	Cytotoxicity against human MT2 cells assessed as reduction in cell viability Cytotoxicity against human MT2 cells assessed as reduction in cell viability	[PMID: 36441509]
MT4	EC₅₀	0.096 μM Compound: 8	Antiviral activity against HIV1 NL4-3 in MT4 cells Antiviral activity against HIV1 NL4-3 in MT4 cells	[PMID: 16942019]
MT4	EC₅₀	0.096 μM Compound: 8	Antiviral activity against HIV1 NL4-3 replication in human MT4 cells Antiviral activity against HIV1 NL4-3 replication in human MT4 cells	[PMID: 16942019]
MT4	EC₅₀	0.43 μM Compound: 8	Antiviral activity against HIV1 PI-R replication in human MT4 cells Antiviral activity against HIV1 PI-R replication in human MT4 cells	[PMID: 16942019]
MT4	IC₅₀	>5 μM Compound: 8	Cytotoxicity against human MT4 cells at 5 uM Cytotoxicity against human MT4 cells at 5 uM	[PMID: 16942019]
MT4	EC₅₀	0.096 μM Compound: 2	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of viral replication after 4 days by p24 antigen based ELISA assay Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of viral replication after 4 days by p24 antigen based ELISA assay	[PMID: 20673723]
MT4	IC₅₀	>5 μM Compound: 2	Cytotoxicity against human MT4 cells after 4 days Cytotoxicity against human MT4 cells after 4 days	[PMID: 20673723]
MT4	IC₅₀	15.2 μM Compound: PA-457	Cytotoxicity against human MT4 lymphocytes after 48 hrs by MTT assay Cytotoxicity against human MT4 lymphocytes after 48 hrs by MTT assay	[PMID: 21123066]
MT4	EC₅₀	>4 μM Compound: BVM	Antiviral activity against bevirimat-resistant HIV1 NL4-3 harboring QVT motif of Gag SP1 deltaT371 mutant infected in human MT4 cells assessed as reduction of viral p24 level cells by fluorescence assay relative to wild type HIV1 NL4-3 after 4 days by ELI Antiviral activity against bevirimat-resistant HIV1 NL4-3 harboring QVT motif of Gag SP1 deltaT371 mutant infected in human MT4 cells assessed as reduction of viral p24 level cells by fluorescence assay relative to wild type HIV1 NL4-3 after 4 days by ELI	[PMID: 22818973]
MT4	EC₅₀	>4 μM Compound: BVM	Antiviral activity against bevirimat-resistant HIV1 NL4-3 harboring QVT motif of Gag SP1 deltaV370 mutant infected in human MT4 cells assessed as reduction of viral p24 level cells by fluorescence assay relative to wild type HIV1 NL4-3 after 4 days by ELI Antiviral activity against bevirimat-resistant HIV1 NL4-3 harboring QVT motif of Gag SP1 deltaV370 mutant infected in human MT4 cells assessed as reduction of viral p24 level cells by fluorescence assay relative to wild type HIV1 NL4-3 after 4 days by ELI	[PMID: 22818973]
MT4	EC₅₀	>4 μM Compound: BVM	Antiviral activity against bevirimat-resistant HIV1 NL4-3 harboring QVT motif of Gag SP1 V370A mutant infected in human MT4 cells assessed as reduction of viral p24 level cells by fluorescence assay relative to wild type HIV1 NL4-3 after 4 days by ELISA Antiviral activity against bevirimat-resistant HIV1 NL4-3 harboring QVT motif of Gag SP1 V370A mutant infected in human MT4 cells assessed as reduction of viral p24 level cells by fluorescence assay relative to wild type HIV1 NL4-3 after 4 days by ELISA	[PMID: 22818973]
MT4	EC₅₀	0.076 μM Compound: BVM	Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as reduction of viral p24 level cells by fluorescence assay relative to wild type HIV1 NL4-3 after 4 days by ELISA Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as reduction of viral p24 level cells by fluorescence assay relative to wild type HIV1 NL4-3 after 4 days by ELISA	[PMID: 22818973]
MT4	CC₅₀	14.2 μM Compound: 2, Bervirimat, DSB, MPC-4326	Cytotoxicity against human MT4 cells after 2 days Cytotoxicity against human MT4 cells after 2 days	[PMID: 22978745]
MT4	IC₅₀	0.087 μM Compound: 2, Bervirimat, DSB, MPC-4326	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as p24 antigen level after 4 days by ELISA Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as p24 antigen level after 4 days by ELISA	[PMID: 22978745]
MT4	CC₅₀	>10 μM Compound: 1	Cytotoxicity against human MT4 cells for 4 days Cytotoxicity against human MT4 cells for 4 days	[PMID: 23379607]
MT4	IC₅₀	>5 μM Compound: 1	Antiviral activity against 0.001 MOI bevirimat-resistant Human immunodeficiency virus 1 NL4-3 harboring gag V370A mutant infected in human MT4 cells assessed as inhibition of viral replication measured 4 days post infection by ELISA Antiviral activity against 0.001 MOI bevirimat-resistant Human immunodeficiency virus 1 NL4-3 harboring gag V370A mutant infected in human MT4 cells assessed as inhibition of viral replication measured 4 days post infection by ELISA	[PMID: 23379607]
MT4	IC₅₀	>6.8 μM Compound: 1	Antiviral activity against 0.001 MOI bevirimat-resistant Human immunodeficiency virus 1 NL4-3 harboring gag T371 deletion mutant infected in human MT4 cells assessed as inhibition of viral replication measured 4 days post infection by ELISA Antiviral activity against 0.001 MOI bevirimat-resistant Human immunodeficiency virus 1 NL4-3 harboring gag T371 deletion mutant infected in human MT4 cells assessed as inhibition of viral replication measured 4 days post infection by ELISA	[PMID: 23379607]
MT4	IC₅₀	>6.8 μM Compound: 1	Antiviral activity against 0.001 MOI bevirimat-resistant Human immunodeficiency virus 1 NL4-3 harboring gag V362I mutant infected in human MT4 cells assessed as inhibition of viral replication measured 4 days post infection by ELISA Antiviral activity against 0.001 MOI bevirimat-resistant Human immunodeficiency virus 1 NL4-3 harboring gag V362I mutant infected in human MT4 cells assessed as inhibition of viral replication measured 4 days post infection by ELISA	[PMID: 23379607]
MT4	IC₅₀	>6.8 μM Compound: 1	Antiviral activity against 0.001 MOI bevirimat-resistant Human immunodeficiency virus 1 NL4-3 harboring gag V370 deletion mutant infected in human MT4 cells assessed as inhibition of viral replication measured 4 days post infection by ELISA Antiviral activity against 0.001 MOI bevirimat-resistant Human immunodeficiency virus 1 NL4-3 harboring gag V370 deletion mutant infected in human MT4 cells assessed as inhibition of viral replication measured 4 days post infection by ELISA	[PMID: 23379607]
MT4	IC₅₀	0.076 μM Compound: 1	Antiviral activity against 0.001 MOI wild type Human immunodeficiency virus 1 NL4-3 infected in human MT4 cells assessed as inhibition of viral replication measured 4 days post infection by ELISA Antiviral activity against 0.001 MOI wild type Human immunodeficiency virus 1 NL4-3 infected in human MT4 cells assessed as inhibition of viral replication measured 4 days post infection by ELISA	[PMID: 23379607]
MT4	CC₅₀	>17 μM Compound: 1; DSB	Cytotoxicity against human MT4 cells by cell-titer Glo assay Cytotoxicity against human MT4 cells by cell-titer Glo assay	[PMID: 26598461]
MT4	EC₅₀	0.075 μM Compound: 1; DSB	Antiviral activity against HIV-1 NL4-3 infected in MT4 cells assessed inhibition of viral replication measured on day 4 postinfection by ELISA Antiviral activity against HIV-1 NL4-3 infected in MT4 cells assessed inhibition of viral replication measured on day 4 postinfection by ELISA	[PMID: 26598461]
MT4	CC₅₀	>4.5 μM Compound: 2	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 2 days by CytoTox-Glo assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 2 days by CytoTox-Glo assay	[PMID: 27676157]
MT4	IC₅₀	0.065 μM Compound: 2	Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells by p24 ELISA Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells by p24 ELISA	[PMID: 27676157]
MT4	IC₅₀	7.71 μM Compound: 2	Antiviral activity against bevirimat-resistant HIV1 NL4-3 harboring GagV370A mutant infected in human MT4 cells by p24 ELISA Antiviral activity against bevirimat-resistant HIV1 NL4-3 harboring GagV370A mutant infected in human MT4 cells by p24 ELISA	[PMID: 27676157]
MT4	CC₅₀	15.9 μM Compound: DSB	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CellTiter-Glo luminescent assay	[PMID: 30703659]
MT4	CC₅₀	>6.84 μM Compound: 3; DSB	Cytotoxicity against human MT4 cells treated for 3 days measured by Celltiter-glo luminescent assay Cytotoxicity against human MT4 cells treated for 3 days measured by Celltiter-glo luminescent assay	[PMID: 33214842]
MT4	CC₅₀	>2 μM Compound: 3	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 2 days by CytoTox-Glo cytotoxicity assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 2 days by CytoTox-Glo cytotoxicity assay	[PMID: 33639343]
Raji	IC₅₀	396 molar ratio Compound: 3	Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA induction after 48 hrs relative to TPA Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA induction after 48 hrs relative to TPA	[PMID: 19481937]
Raji	IC₅₀	396 molar ratio Compound: Bevirimat	Chemopreventive activity in human Raji cells assessed as molar ratio of compound required to inhibit 50% of control of inhibition of TPA-induced EBV-early antigen activation after 48 hrs by immunofluorescence analysis Chemopreventive activity in human Raji cells assessed as molar ratio of compound required to inhibit 50% of control of inhibition of TPA-induced EBV-early antigen activation after 48 hrs by immunofluorescence analysis	[PMID: 24411124]
THP-1	IC₅₀	54 μM Compound: 25, bevirimat	Cytotoxicity against human THP1 cells assessed as cell viability after 48 hrs by AlamarBlue assay Cytotoxicity against human THP1 cells assessed as cell viability after 48 hrs by AlamarBlue assay	10.1039/C3MD00282A
TZM	EC₅₀	>17.1 μM Compound: 8	Inhibition of membrane fusion between HIV1 NL4-3 envelope gene expressing COS cells and TZM cells Inhibition of membrane fusion between HIV1 NL4-3 envelope gene expressing COS cells and TZM cells	[PMID: 16942019]

In Vitro

Bevirimat inhibits wild-type HIV-1 replication with a mean IC₅₀ of 10.3 nM^[2].
Bevirimat (72 h) shows antiviral activity against wild type HIV1 and HIV1 harboring capsid I201V mutant protein infected in human HeLa cells, with a EC₅₀ of 0.009 and 0.29 μM^[3].
Bevirimat (48 h) shows cytotoxicity against mock-infected human MT2 cells, with a CC₅₀ of > 10 μM^[4].
Bevirimat (1 day) shows antiviral activity against HIVIIIB infected in human MT2 cells assessed as inhibition of viral replication, with a EC₅₀ of 0.0013 μM^[5].
Bevirimat (48 h) shows cytotoxicity against human MT4 cells assessed as reduction in cell viability by CytoTox-Glo cytotoxicity assay, with a CC₅₀ of > 2 μM^[6].
Bevirimat (4 days) shows antiviral activity against HIV1_NL4-3 infected in human MT4 cells assessed as p24 antigen level, with a IC₅₀ of 0.087 μM^[7].
Bevirimat (3 days) shows cytotoxicity against HIV-1-infected C8166 cells, with a mean CC₅₀ of 53.23 μM^[9].
Bevirimat (0-8 μM, 3 days) has a weak inhibitory effect on the replication of HIV-1IIIB in C8166 cells in the presence of 20% human serum^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Bevirimat (10-100 mg/kg, p.o., twice-daily, 22 days) potently inhibits HIV-1 replication and prevents thymocyte depletion in SCID-hu Thy/Liv mice^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male C.B-17 SCID-hu Thy/Liv mice (implanted with tissues from a single donor; implants were inoculated 18 weeks after implantation with 50 µL of stock virus (500–2,000 50% tissue-culture infectious doses) or RPMI 1640 medium (mock infection) by direct injection)^[8]
Dosage:

10, 30, and 100 mg/kg
Administration:

Oral gavage (p.o.), beginning 1 day before inoculation by direct injection of the Thy/Liv implants and continuing until implant collection 21 days after inoculation
Result:

Inhibited viral replication in a dose-dependent manner, reducing implant HIV-1 RNA by 2.1 log10 copies, p24 by 96%, and Gag-p24⁺ thymocytes from 7% to <1% at 100 mg/kg per day when compared with untreated mice.
Caused significant protection of the implants from virus-mediated loss of cellularity at 10 and 30 mg/kg per day, from depletion of CD4⁺CD8⁺ thymocytes at 100 mg/kg per day, and from a reduction in CD4/CD8 ratio at 30 and 100 mg/kg per day.

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

No. CAS 174022-42-5
Appearance Solid
Peso molecular 584.83
Fòrmula C₃₆H₅₆O₆
Color White to off-white
SMILES

OC([C@]1(CC[C@H]2C(C)=C)[C@@]2([H])[C@](CC[C@@]3([H])[C@]4(CC[C@]5([H])[C@@]3(CC[C@H](OC(CC(C)(C)C(O)=O)=O)C5(C)C)C)C)([H])[C@@]4(C)CC1)=O
Synonyms

PA-457; MPC-4326; YK FH312
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (2)

All

Sort by:

Journal Impact Factor

Int J Antimicrob Agents

Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro. [Abstract]

2019 Dec;54(6):814-819. PMID: 31479744
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607

Solvente y solubilidad

In Vitro:

DMSO : ≥ 50 mg/mL (85.49 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7099 mL

8.5495 mL

17.0990 mL

5 mM

0.3420 mL

1.7099 mL

3.4198 mL

10 mM

0.1710 mL

0.8549 mL

1.7099 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (4.27 mM); Suspended solution; Need ultrasonic and warming

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (281 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Martin DE, et al. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13. [Content Brief]

[2]. Li F, et al. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13555-60. [Content Brief]

[3]. Blair WS, et al. New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation. Antimicrob Agents Chemother. 2009 Dec;53(12):5080-7. [Content Brief]

[4]. Callies O, et al. Isolation, Structural Modification, and HIV Inhibition of Pentacyclic Lupane-Type Triterpenoids from Cassine xylocarpa and Maytenus cuzcoina. J Nat Prod. 2015 May 22;78(5):1045-55. [Content Brief]

[5]. Qian K, et al. Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors. J Med Chem. 2010 Apr 22;53(8):3133-41. [Content Brief]

[6]. Zhao Y, et al. Design, synthesis, and structure activity relationship analysis of new betulinic acid derivatives as potent HIV inhibitors. Eur J Med Chem. 2021 Apr 5;215:113287. [Content Brief]

[7]. Qian K, et al. Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors. J Med Chem. 2012 Sep 27;55(18):8128-36. [Content Brief]

[8]. Stoddart CA, et al. Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice. PLoS One. 2007 Nov 28;2(11):e1251. [Content Brief]

[9]. Zhao L, et al. Pre-clinical pharmacological profile of QF-036, a potent HIV-1 maturation inhibitor. Basic Clin Pharmacol Toxicol. 2021 Feb;128(2):275-285. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7099 mL	8.5495 mL	17.0990 mL	42.7475 mL
	5 mM	0.3420 mL	1.7099 mL	3.4198 mL	8.5495 mL
	10 mM	0.1710 mL	0.8549 mL	1.7099 mL	4.2747 mL
	15 mM	0.1140 mL	0.5700 mL	1.1399 mL	2.8498 mL
	20 mM	0.0855 mL	0.4275 mL	0.8549 mL	2.1374 mL
	25 mM	0.0684 mL	0.3420 mL	0.6840 mL	1.7099 mL
	30 mM	0.0570 mL	0.2850 mL	0.5700 mL	1.4249 mL
	40 mM	0.0427 mL	0.2137 mL	0.4275 mL	1.0687 mL
	50 mM	0.0342 mL	0.1710 mL	0.3420 mL	0.8549 mL
	60 mM	0.0285 mL	0.1425 mL	0.2850 mL	0.7125 mL
	80 mM	0.0214 mL	0.1069 mL	0.2137 mL	0.5343 mL

Bevirimat

2 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Bevirimat

Anti-Infection Compound Library

Natural Product Library

Clinical Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Traditional Chinese Medicine Active Compound Library

Antiviral Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Protease Inhibitor Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Fatty Acids Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Bevirimat

Actividad biológica

Chemical Information

Publications (2)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Bevirimat

Anti-Infection Compound Library

Natural Product Library

Clinical Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Traditional Chinese Medicine Active Compound Library

Antiviral Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Protease Inhibitor Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Fatty Acids Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Bevirimat

Actividad biológica

Chemical Information

Publications (2)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Bevirimat Related Classifications

Referencia número: HY-N0842